Board of Scientific Counselors, Coordinating Center for Infectious Diseases, (BSC, CCID), 7283-7284 [2010-3056]
Download as PDF
<![CDATA[
WReier-Aviles on DSKGBLS3C1PROD with NOTICES
Federal Register / Vol. 75, No. 32 / Thursday, February 18, 2010 / Notices
20993, 301–796–6313, e-mail:
James.Swink@fda.hhs.gov, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area), code
3014512625. Please call the Information
Line for up-to-date information on this
meeting. A notice in the Federal
Register about last minute modifications
that impact a previously announced
advisory committee meeting cannot
always be published quickly enough to
provide timely notice. Therefore, you
should always check the agency’s Web
site and call the appropriate advisory
committee hot line/phone line to learn
about possible modifications before
coming to the meeting.
Agenda: On March 18, 2010, the
committee will discuss, make
recommendations, and vote on the
premarket approval application (PMA)
for the Cardiac Resynchronization
Therapy Defibrillators (CRT–Ds)
sponsored by Boston Scientific. The
sponsor is seeking expanded indications
for the their CRT–Ds to include patients
with low left ventricular ejection
fraction (≤30%) and wide QRS (≥130
ms) who are NYHA Class II (ischemic or
non-ischemic etiology) or NYHA Class I
(ischemic etiology).
On March 19, 2010, the committee
will discuss, make recommendations
and vote on a PMA for the REVO MRI
Pacemaker System sponsored by
Medtronic. The REVO MRI Pacing
System is a pacemaker (with a standard
pacing indication) that has been
specifically designed to be safe for the
MRI environment under certain MR
scanning conditions.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm, scroll down to the
appropriate advisory committee link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before March 11, 2010.
Oral presentations from the public will
be scheduled immediately following
lunch. Those desiring to make formal
oral presentations should notify the
contact person and submit a brief
statement of the general nature of the
VerDate Nov<24>2008
14:39 Feb 17, 2010
Jkt 220001
evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before March 3, 2010. Time allotted
for each presentation may be limited. If
the number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by March 4, 2010.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact AnnMarie
Williams at 301–796–5966 at least 7
days in advance of the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/Advisory
Committees/AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: February 4, 2010.
Jill Hartzler Warner,
Acting Associate Commissioner for Special
Medical Programs.
[FR Doc. 2010–3032 Filed 2–17–10; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Strengthening
Global Human-Animal Interface
Activities for Avian Influenza and Other
Zoonotic Diseases, Funding
Opportunity Announcement (FOA)
CK10–001, Initial Review
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the aforementioned meeting:
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
7283
Time and Date: 12 p.m.–2 p.m., April 7,
2010 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in Section 552b(c)(4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Matters To Be Discussed: The meeting will
include the initial review, discussion, and
evaluation of applications received in
response to ‘‘Strengthening Global HumanAnimal Interface Activities for Avian
Influenza and other Zoonotic Diseases, FOA
CK10–001.’’
Contact Person for More Information:
Gregory Anderson, M.S., M.P.H., Scientific
Review Officer, CDC, 1600 Clifton Road, NE.,
Mailstop E60, Atlanta, GA 30333, Telephone:
(404) 498–2293.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both CDC and the Agency for Toxic
Substances and Disease Registry.
Dated: February 11, 2010.
Andre Tyler,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. 2010–3141 Filed 2–17–10; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Board of Scientific Counselors,
Coordinating Center for Infectious
Diseases, (BSC, CCID)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC),
announces the following meeting of the
aforementioned committee:
Time and Date: 10 a.m.–11 a.m., March 2,
2010.
Place: Teleconference.
Status: Open to the public, the toll free dial
in number is 1–866–880–0098 with a pass
code of 9887280.
Purpose: The BSC, CCID shall advise the
Secretary, HHS, and the Director, CDC
concerning strategies and goals for the
programs and research within the national
centers; will administer and oversee peer
review of scientific programs; and monitor
the overall strategic direction and focus of
the national centers.
Matters To Be Discussed: Agenda items
will include:
1. Update from Dr. Khabbaz.
2. Update on H1N1 response.
3. Update from National Center for HIV/
AIDS, Viral Hepatitis, STD, and TB
Prevention.
E:\FR\FM\18FEN1.SGM
18FEN1
7284
Federal Register / Vol. 75, No. 32 / Thursday, February 18, 2010 / Notices
4. Update from National Center for
Immunization and Respiratory Diseases.
5. Update from National Center for
Emerging and Zoonotic Infectious Diseases.
6. Plan the May meeting.
Written comments are welcome and should
be received by the contact person listed
below prior to the opening of the meeting.
Agenda items are subject to change as
priorities dictate.
For More Information Contact: Leola
Mitchell, Office of the Director, CCID, CDC,
Mailstop E06, 1600 Clifton Road, NE.,
Atlanta, Georgia 30333, Telephone (404)
639–6405, e-mail: fvp9@cdc.gov.
The Director, Management Analysis and
Services Office has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both CDC and the Agency for Toxic
Substances and Disease Registry.
Dated: February 8, 2010.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2010–3056 Filed 2–17–10; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
organizations, including State and local
government agencies, to conduct
research that will expand and advance
the understanding of violence, its
causes, and prevention strategies.
Matters To Be Discussed: The meeting
will include the review, discussion, and
evaluation of applications intended to
expand and advance the understanding
of violence, its causes, and prevention
strategies. Requests for Applications are
related to the following individual
research announcement: CE10–005,
Research Grants for Preventing Violence
and Violence–Related Injury.
Agenda items are subject to change as
priorities dictate.
Contact Person for More Information:
J. Felix Rogers, PhD, M.P.H., NCIPC,
CDC, 4770 Buford Highway, NE.,
MailStop F63, Atlanta, Georgia 30341,
Telephone: (770) 488–4334.
The Director, Management Analysis
and Services Office has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities for both CDC and
the Agency for Toxic Substances and
Disease Registry.
National Center for Injury Prevention
and Control/Initial Review Group,
(NCIPC/IRG)
WReier-Aviles on DSKGBLS3C1PROD with NOTICES
Centers for Disease Control and
Prevention
Dated: February 10, 2010.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2010–3048 Filed 2–17–10; 8:45 am]
BILLING CODE 4163–18–P
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC),
announces the following meeting of the
aforementioned review group:
Times and Dates: 8 a.m.–5 p.m.,
March 11, 2010 (Closed).
8 a.m.–5 p.m., March 12, 2010
(Closed).
Place: JW Marriott Hotel Buckhead,
3300 Lenox Road, Atlanta, Georgia
30326, Telephone: (404) 262–3344.
Status: The meetings will be closed to
the public in accordance with
provisions set forth in Section
552b(c)(4) and (6), Title 5, U.S.C., and
the Determination of the Director,
Management Analysis and Services
Office, CDC, pursuant to Section 10(d)
of Public Law 92–463.
Purpose: This group is charged with
providing advice and guidance to the
Secretary, Department of Health and
Human Services, and the Director, CDC,
concerning the scientific and technical
merit of grant and cooperative
agreement applications received from
academic institutions and other public
and private profit and nonprofit
VerDate Nov<24>2008
14:39 Feb 17, 2010
Jkt 220001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Institutional
Collaboration Between Liverpool
School of Tropical Medicine and the
Centers for Disease Control and
Prevention on Malaria, Funding
Opportunity Announcement (FOA)
CK10–002, Initial Review
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the aforementioned meeting:
Time and Date: 12 p.m.—2 p.m., April 12,
2010 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in Section 552b(c) (4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
Matters To Be Discussed: The meeting will
include the initial review, discussion, and
evaluation of applications received in
response to ‘‘Institutional Collaboration
between Liverpool School of Tropical
Medicine and the Centers for Disease Control
and Prevention on Malaria, FOA CK10–002.’’
Contact Person for More Information:
Gregory Anderson, M.S., M.P.H., Scientific
Review Officer, CDC, 1600 Clifton Road, NE.,
Mailstop E60, Atlanta, GA 30333, Telephone:
(404) 498–2293.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both CDC and the Agency for Toxic
Substances and Disease Registry.
Dated: February 10, 2010.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2010–3049 Filed 2–17–10; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket Number NIOSH 099–C]
NIOSH Current Intelligence Bulletin—
Asbestos Fibers and Other Elongate
Mineral Particles: State of the Science
and Roadmap for Research, Version 4
AGENCY: National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC),
Department of Health and Human
Services (HHS).
ACTION: Notice of Draft Document
Available for Public Comment.
SUMMARY: The National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC)
announces the following revised draft
document available for public comment
entitled ‘‘NIOSH Current Intelligence
Bulletin—Asbestos Fibers and Other
Elongate Mineral Particles: State of the
Science and Roadmap for Research,
Version 4.’’ The document and
instructions for submitting comments
can be found at https://www.cdc.gov/
niosh/review/public/099–C/.
Public Comment Period: February 18,
2010 through April 16, 2010.
Status: Written comments may be
mailed to the attention of the NIOSH
Docket Officer, NIOSH Docket Office,
Robert A. Taft Laboratories, 4676
Columbia Parkway (M/S C34),
Cincinnati, Ohio 45226, telephone (513)
E:\FR\FM\18FEN1.SGM
18FEN1
]]>Agencies
[Federal Register Volume 75, Number 32 (Thursday, February 18, 2010)]
[Notices]
[Pages 7283-7284]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-3056]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Board of Scientific Counselors, Coordinating Center for
Infectious Diseases, (BSC, CCID)
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC), announces the following meeting of the aforementioned
committee:
Time and Date: 10 a.m.-11 a.m., March 2, 2010.
Place: Teleconference.
Status: Open to the public, the toll free dial in number is 1-
866-880-0098 with a pass code of 9887280.
Purpose: The BSC, CCID shall advise the Secretary, HHS, and the
Director, CDC concerning strategies and goals for the programs and
research within the national centers; will administer and oversee
peer review of scientific programs; and monitor the overall
strategic direction and focus of the national centers.
Matters To Be Discussed: Agenda items will include:
1. Update from Dr. Khabbaz.
2. Update on H1N1 response.
3. Update from National Center for HIV/AIDS, Viral Hepatitis,
STD, and TB Prevention.
[[Page 7284]]
4. Update from National Center for Immunization and Respiratory
Diseases.
5. Update from National Center for Emerging and Zoonotic
Infectious Diseases.
6. Plan the May meeting.
Written comments are welcome and should be received by the
contact person listed below prior to the opening of the meeting.
Agenda items are subject to change as priorities dictate.
For More Information Contact: Leola Mitchell, Office of the
Director, CCID, CDC, Mailstop E06, 1600 Clifton Road, NE., Atlanta,
Georgia 30333, Telephone (404) 639-6405, e-mail: fvp9@cdc.gov.
The Director, Management Analysis and Services Office has been
delegated the authority to sign Federal Register notices pertaining
to announcements of meetings and other committee management
activities, for both CDC and the Agency for Toxic Substances and
Disease Registry.
Dated: February 8, 2010.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2010-3056 Filed 2-17-10; 8:45 am]
BILLING CODE 4163-18-P
